Physician profile
Frederick Harris
NPI 1447478755
$10,302.96
in general payments reported to CMS, 2019-2025
36 companies · $2,248 in 2025
The $2,248 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,477 · 2020: $368 · 2021: $460 · 2022: $2,361 · 2023: $1,777 · 2024: $1,614 · 2025: $2,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,553 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,553.33 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,271.29 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $1,867.50 | 2019-2025 | |
| Gilead Sciences, INC. | $851.01 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $806.78 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $683.11 | 2019-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $505.54 | 2022-2025 | |
| Celgene Corporation | $292.42 | 2022-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $289.23 | 2024-2025 | Iqirvo |
| Pfizer INC. | $285.32 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $236.31 | 2019-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $225.96 | 2019-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $225.92 | 2021-2023 | |
| Qol Medical, LLC | $211.42 | 2019-2025 | Sucraid, Sucraid |
| Medtronic, INC. | $193.65 | 2022 | |
| Ferring Pharmaceuticals INC. | $191.17 | 2019-2023 | Rebyota |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $182.96 | 2025 | Rezdiffra |
| Lilly USA, LLC | $141.02 | 2023-2025 | Omvoh, Zepbound |
| Regeneron Healthcare Solutions, INC. | $138.31 | 2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $125.32 | 2024-2025 | Voquezna |
| Amgen INC. | $101.82 | 2022-2025 | Amjevita, Avsola, Uplizna |
| Ironwood Pharmaceuticals, INC | $99.41 | 2021-2024 | Linzess |
| Ucb, INC. | $54.58 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $46.21 | 2025 | Zenpep |
| Evoke Pharma, INC. | $43.02 | 2022-2024 | Gimoti |
| Braintree Laboratories, INC. | $34.11 | 2022-2025 | Suflave |
| Ardelyx, INC. | $32.66 | 2023-2024 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $26.55 | 2022 | |
| Shire North American Group INC | $24.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.19 | 2023 | Cyltezo |
| Orphalan INC | $16.26 | 2025 | Cuvrior |
| Redhill Biopharma INC. | $15.61 | 2022 | |
| Celltrion USA INC. | $15.06 | 2025 | Vegzelma |
| Olympus America INC. | $14.52 | 2020 | |
| Daiichi Sankyo INC. | $14.46 | 2019 | |
| Alfasigma USA, INC. | $11.47 | 2020 | |
| Vivus LLC | $8.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.